- Previous Close
0.6650 - Open
1.0000 - Bid 0.8793 x 100
- Ask 0.9466 x 100
- Day's Range
0.7895 - 1.1700 - 52 Week Range
0.5510 - 49.0000 - Volume
69,916,173 - Avg. Volume
121,720 - Market Cap (intraday)
66.544M - Beta (5Y Monthly) -0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
--
Full Time Employees
September 30
Fiscal Year Ends
Sector
Recent News: CTOR
View More
Performance Overview: CTOR
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTOR
View MoreValuation Measures
Market Cap
47.58M
Enterprise Value
51.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.24%
Return on Equity (ttm)
-72.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.08M
Diluted EPS (ttm)
-0.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
112
Total Debt/Equity (mrq)
9.20%
Levered Free Cash Flow (ttm)
-1.26M